BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9406691)

  • 1. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
    Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
    Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
    Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
    Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
    J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96.
    Chen JQ; Strand SE; Tennvall J; Lindgren L; Hindorf C; Sjögren HO
    J Nucl Med; 1997 Dec; 38(12):1934-9. PubMed ID: 9430473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats.
    Garkavij M; Tennvall J; Strand SE; Norrgren K; Lindgren L; Nilsson R; Sjögren HO
    Cancer Res; 1995 Dec; 55(23 Suppl):5874s-5880s. PubMed ID: 7493363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method.
    Garkavij M; Tennvall J; Strand SE; Nilsson R; Lindgren L; Chen J; Isaksson M; Eriksson H; Sjögren H
    Acta Oncol; 1996; 35(3):309-12. PubMed ID: 8679261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA).
    Garkavij M; Tennvall J; Strand SE; Norrgren K; Nilsson R; Lindgren L; Sjögren HO
    Acta Oncol; 1993; 32(7-8):853-9. PubMed ID: 8305236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
    Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
    J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio.
    Strand SE; Norrgren K; Garkavij M; Lindgren L; Nilsson R; Sjogren HO; Tennvall J
    Cancer; 1994 Feb; 73(3 Suppl):1033-7. PubMed ID: 8306245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
    Wang Z; Garkavij M; Ohlsson T; Strand SE; Sjögren HO; Tennvall J
    Cancer Biother Radiopharm; 2003 Jun; 18(3):365-75. PubMed ID: 12954123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A general, extracorporeal immunoadsorption method to increase the tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy.
    Norrgren K; Strand SE; Nilsson R; Lindgren L; Sjögren HO
    J Nucl Med; 1993 Mar; 34(3):448-54. PubMed ID: 8441037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
    Mårtensson L; Nilsson R; Sjögren HO; Strand SE; Tennvall J
    Artif Organs; 2007 Apr; 31(4):312-6. PubMed ID: 17437500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.
    Wang Z; Garkavij M; Tennvall JG; Ohlsson T; Strand SE; Sjögren HO
    Cancer; 2002 Feb; 94(4 Suppl):1287-92. PubMed ID: 11877758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental approaches to increase radiolabeled antibody localization in tumors.
    Buchsbaum DJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5729s-5732s. PubMed ID: 7493336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood.
    Kurkus J; Nilsson R; Lindén O; Schönström N; Sandberg BE; Tennvall J
    Artif Organs; 2007 Mar; 31(3):208-14. PubMed ID: 17343696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving radioimmunotargeting of tumors: the impact of preloading unlabeled L6 monoclonal antibody on the biodistribution of 125I-L6 in rats.
    Garkavij M; Tennvall J; Strand SE; Norrgren K; Nilsson R; Sjögren HO
    J Nucl Biol Med (1991); 1994 Dec; 38(4):594-600. PubMed ID: 7786923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.